Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Pascal Touchon Sells 15,679 Shares

Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Rating) CEO Pascal Touchon sold 15,679 shares of the business’s stock in a transaction that occurred on Thursday, March 2nd. The stock was sold at an average price of $3.63, for a total value of $56,914.77. Following the completion of the transaction, the chief executive officer now directly owns 750,728 shares in the company, valued at $2,725,142.64. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Atara Biotherapeutics Stock Performance

ATRA opened at $3.43 on Tuesday. The firm has a market cap of $329.04 million, a P/E ratio of -1.54 and a beta of 0.99. Atara Biotherapeutics, Inc. has a fifty-two week low of $2.83 and a fifty-two week high of $10.01. The firm has a 50-day moving average of $4.15 and a 200 day moving average of $4.18.

Atara Biotherapeutics (NASDAQ:ATRA – Get Rating) last announced its quarterly earnings data on Wednesday, February 8th. The biotechnology company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.61) by ($0.11). The firm had revenue of $0.22 million for the quarter, compared to analysts’ expectations of $60.00 million. Atara Biotherapeutics had a negative net margin of 359.12% and a negative return on equity of 140.05%. Equities research analysts predict that Atara Biotherapeutics, Inc. will post -2.28 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Atara Biotherapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. State Street Corp increased its stake in shares of Atara Biotherapeutics by 45.1% during the first quarter. State Street Corp now owns 6,273,617 shares of the biotechnology company’s stock worth $58,282,000 after purchasing an additional 1,949,418 shares in the last quarter. Wasatch Advisors Inc. boosted its holdings in Atara Biotherapeutics by 88.8% in the first quarter. Wasatch Advisors Inc. now owns 3,823,588 shares of the biotechnology company’s stock valued at $35,521,000 after purchasing an additional 1,798,072 shares during the period. Goldman Sachs Group Inc. boosted its holdings in Atara Biotherapeutics by 41.9% in the first quarter. Goldman Sachs Group Inc. now owns 3,638,106 shares of the biotechnology company’s stock valued at $33,798,000 after purchasing an additional 1,073,579 shares during the period. Norges Bank purchased a new stake in Atara Biotherapeutics during the 4th quarter worth about $2,849,000. Finally, JPMorgan Chase & Co. lifted its holdings in Atara Biotherapeutics by 8.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 8,861,252 shares of the biotechnology company’s stock worth $69,029,000 after buying an additional 671,353 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on ATRA. HC Wainwright reduced their price target on Atara Biotherapeutics from $29.00 to $27.00 and set a “buy” rating for the company in a report on Thursday, February 9th. EF Hutton Acquisition Co. I restated a “buy” rating and issued a $25.00 price target on shares of Atara Biotherapeutics in a research report on Thursday, February 9th. Finally, Mizuho reissued a “buy” rating and set a $31.00 price target on shares of Atara Biotherapeutics in a research note on Tuesday, February 7th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $19.25.

About Atara Biotherapeutics

(Get Rating)

Atara Biotherapeutics, Inc is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need.